New bladder cancer drug put to the test in early study
NCT ID NCT05014139
First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tested a drug called enfortumab vedotin for people with a type of bladder cancer that hasn't spread into the muscle layer. The drug was placed directly into the bladder using a thin tube. The main goals were to check for side effects and see how the body handles the drug. The study was stopped early and included 37 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Erlanger Oncology and Hematology
Chattanooga, Tennessee, 37403, United States
-
Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington
Seattle, Washington, 98195, United States
-
James Cancer Hospital / Ohio State University
Columbus, Ohio, 43221, United States
-
Johns Hopkins Medical Center
Baltimore, Maryland, 21287, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Markey Cancer Center / University of Kentucky
Lexington, Kentucky, 40508, United States
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Northwestern University-Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Oregon Health and Science University
Portland, Oregon, 98682, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, 19107, United States
-
Site CA11001
Toronto, Ontario, M5G 2C1, Canada
-
Site DE49001
Göttingen, 37075, Germany
-
Site DE49002
Tübingen, 72076, Germany
-
Site ES34001
Barcelona, 08025, Spain
-
Site ES34002
Madrid, 28041, Spain
-
Site ES34003
Barcelona, 08036, Spain
-
Site ES34004
Barcelona, 08035, Spain
-
Site FR33001
Paris, 75013, France
-
Site FR33002
Lyon, 69003, France
-
Site FR33003
Rennes, 35000, France
-
Site UK44002
London, EC1A 7BE, United Kingdom
-
Stanford Health Care
Stanford, California, 94305, United States
-
UCLA Department of Medicine - Hematology & Oncology
Los Angeles, California, 90095, United States
-
University of California at San Francisco
San Francisco, California, 94134, United States
-
University of California, Irvine
Orange, California, 92868, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Urology San Antonio
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.